Previous view $625M-$640M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa reports Q3 EPS 23c, consensus 37c
- Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
- KNSA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals
- Kiniksa announces Orphan Drug Designation for KPL-387